Key takeaways

  • Unitree priced its Shanghai STAR Market debut at 150.8 yuan per share, valuing the company at about ¥61 bn ($9.0 bn). The IPO seeks to raise ¥6.1 bn, far above the earlier ¥4.2 bn target that implied a $5.9 bn market cap.
  • A week of financing added more than $1.2 bn to the sector: Walden ($300 M seed at $1.1 bn), LimX ($200 M pre‑IPO at $2.21 bn), AI² ($735 M raise with $2‑3 bn valuation range) and Agility’s $620 M SPAC proceeds.
  • U.S.–China tech frictions have spawned fresh export restrictions on foreign‑made humanoids, while China’s industry ministry projects >100 k units shipped in 2026.
  • Production milestones stack up: Tesla cleared its Fremont line for Optimus (no robots running yet), Boston Dynamics piloted Spot for last‑mile delivery, and 1X unveiled 25‑DoF NEO hands.
  • Real‑world use cases are emerging—from Walden bots on a Toyota line to Unitree G1 platforms used in live‑pig surgery, and the first humanoid‑robot strike at Hyundai.

Valuation Battle: Unitree’s IPO Price vs Early Estimates

Unitree’s prospectus disclosed a share price of 150.8 yuan ($22.34), which translates to a ¥61 bn ($9.04 bn) valuation. The filing also states the company is seeking to raise ¥6.1 bn.

Earlier coverage from the STAR Market prospectus described a ¥4.2 bn ($618 M) raise, selling 40.45 million shares (≥10 % of capital) and implying a ¥42 bn ($5.9 bn) market cap. The gap between the two numbers shows how quickly market sentiment has shifted in the weeks leading up to the listing.

Capital Influx: Funding Waves Across the Humanoid Landscape

In a single week, three firms secured $1.2 bn+ in fresh capital:

  • Walden Robotics emerged from stealth with a $300 M seed at a $1.1 bn valuation and already claims to be running production robots at a Toyota plant in North America since February.
  • LimX Dynamics closed a $200 M pre‑IPO round at a $2.21 bn post‑money valuation.
  • AI² Robotics raised roughly $735 M; reported valuations differ between $2 bn and $3 bn.

Separately, Agility Robotics filed a draft S‑4 for a $2.5 bn merger with Churchill Capital XI, expecting > $620 M proceeds and a $200 M PIPE led by Foxconn.

Regulation & Geopolitics: U.S.–China Tech Tensions Shape the Playbook

The IPO lands amid escalating trade friction. CNBC notes that Washington has imposed new restrictions on foreign‑made humanoid and quadruped robots, while Beijing has responded with its own export curbs.

Unitree disclosed that U.S. sales made up 13.3 % of revenue in the prior year, and warned that tariffs, export controls or loss of approvals could hurt overseas growth.

Domestically, China’s industry ministry projects >100 k humanoid units shipped in 2026, while IEEE Spectrum documented Ukraine ordering 50 k ground robots for 2026— a clear signal that governments are now major buyers.

Market Momentum: Production Milestones & Real‑World Deployments

Tesla’s Optimus Factory Build‑out

Tesla removed the Fremont Model S/X production line and cleared the floor for its first Optimus line. Elon Musk publicly said no Optimus robots were producing parts as of mid‑July, though the company frames the line as a step toward one‑million robots a year.

Spot’s Last‑Mile Delivery Pilot

Boston Dynamics demonstrated a Spot‑based “porch‑gap” concept: the robot rides in a delivery van, walks the last ~50 ft to a doorstep and carries two parcels at a time. The pilot targets 200 packages per day on routes that start with manual driving before shifting to autonomous runs.

1X NEO Hand Upgrade

1X released a 25‑DoF tendon‑driven hand for its NEO platform, quoting ±0.2 mm positioning, 45 N fingertip force, IP68 food‑safe construction, and pricing at $20 k outright or $499/mo.

Clinical Firsts with Unitree G1

Researchers at UC San Diego performed live‑pig gallbladder removals using two $20 k Unitree G1 humanoids, piloted by human surgeons. The work proves that a general‑purpose, sub‑$30 k robot can enter the operating room, a stark contrast to $2 M‑plus dedicated surgical platforms.

Labor Pushback: Hyundai’s Robot Strike

Around 35 k Hyundai workers staged the first humanoid‑robot strike, demanding that no Atlas robot be deployed without a labor‑management agreement. Atlas units currently cost $130‑140 k each, but Hyundai expects the price to fall to $30 k after 50 k units are produced.

Comparative Snapshot

Company Latest Funding / IPO Valuation (post‑money) 2025 Revenue (reported) Key Product / Milestone
Unitree IPO pricing 150.8 ¥/share, raise ¥6.1 bn ¥61 bn ($9.0 bn) ¥1.7 bn total; ¥867.8 m from humanoids H2 Plus research platform; G1 used in live‑pig surgery
Walden Robotics $300 M seed $1.1 bn Not disclosed (claims production at Toyota plant) General‑purpose bots on a Toyota line
LimX Dynamics $200 M pre‑IPO $2.21 bn Not disclosed Humanoid platforms for manufacturing
AI² Robotics $735 M raise $2‑3 bn (conflict) Not disclosed Wheeled AlphaBot humanoids
Agility Robotics $620 M SPAC proceeds + $200 M PIPE $2.5 bn merger value Not disclosed Digit industrial humanoid
Tesla (Optimus) Internal financing (no IPO) N/A Not disclosed Fremont line cleared; target 1 M units/yr
Boston Dynamics (Spot) Internal R&D N/A Not disclosed 50‑ft last‑mile delivery pilot

Conclusion

The Unitree IPO has created a pricing anchor for pure‑play humanoid makers, but the market now spans a spectrum—from $20 k research bots to $130 k industrial Atlas units. Capital is flooding in, yet every raise is accompanied by regulatory scrutiny: export bans, labor activism, and geopolitical tariffs all shape the path to commercial scale. As we track shipments, factory line conversions, and the first clinical procedures, investors should weigh the valuation spread, regulatory risk, and real‑world traction of each player rather than the hype surrounding a single headline.

Sources

This article was researched and fact-checked against the following sources: